The peritoneal dialysis equipment market is projected to reach US$ 2,930.45 million by 2031 from US$ 2,324.40 million in 2024. The market is estimated to register a CAGR of 3.5% during 2025-2031. Major factors driving the market growth include the rising prevalence of chronic kidney disease and end-stage renal disease, preference for home-based & patient-centric care, and supportive policies & reimbursement & awareness are propelling the adoption of peritoneal dialysis equipment. Further, emerging/underserved market penetration will likely boost the market during the forecast period. However, risk of peritonitis and catheter-related complications, lack of infrastructure & trained personnel, high initial cost / maintenance & operational complexity are among the market deterrents.

In various regions, the response of governments and health systems to patient needs has led them to implement policies, change reimbursements, and run awareness programs, which are favorable to peritoneal dialysis (PD) and, consequently, to the demand for PD equipment and related accessories. Taiwan is a good example of this change, as it launched a reimbursement initiative in July 2023 through its National Health Insurance to reverse the declining trend in PD utilization. The new policy offers financial support to areas where PD is practiced, helps create new PD units, requires training of staff on PD, facilitates collaboration between medical centers and community clinics, and allows reimbursement of telemedicine video sessions, which supports the choice of PD modality.

Awareness activities also play a significant role in changing the way people choose the mode of dialysis. For example, Baxter in India started a campaign "Choose Freedom" at the beginning of 2023 to reach the CKD/ESKD patients with the message of PD, promote shared decision-making among patients, families, and clinicians, and help patients know that PD can keep their independence and the quality of their lives. On the other hand, community and nonprofit organizations are not inactive in this field because, with the TANKER Foundation in Tamil Nadu setting the lead, by May 2025, they have done 1,494 programs engaging more than 213,500 people, and organized 627 screening camps to facilitate early intervention after identifying the kidney disease risk through screening.

Supportive policy and reimbursement, along with awareness, are significant contributors to the growth of PD, especially in countries with a well-established public health system or where nonprofits/industry partners are actively involved in creating awareness and aligning incentives in favor of PD.

The comparative company analysis evaluates and categorizes the peritoneal dialysis equipment market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global peritoneal dialysis equipment market. The key market players are Asahi Kasei Corp, Fresenius Medical Care AG & Co KGaA, Baxter International Inc, B. Braun Melsungen AG, Medtronic Plc, Terumo Corp, Utah Medical Products Inc, Angiplast, BD, and Poly Medicure Ltd.

In terms of product type, the peritoneal dialysis equipment market is bifurcated into peritoneal dialysis solution, peritoneal dialysis catheters, peritoneal dialysis transfer sets, and others. The peritoneal dialysis solution segment held a larger market share in 2024, owing to cost-effective and patient-friendly treatment option that is leading the peritoneal dialysis equipment market.

Based on dialysis type, the peritoneal dialysis equipment market is categorized into continuous ambulatory peritoneal dialysis (CAPD), automated peritoneal dialysis (APD). The continuous ambulatory peritoneal dialysis (CAPD) segment accounted for the largest share of the peritoneal dialysis equipment market in 2024. Recent advancements have focused on enhancing the safety, efficiency, and user-friendliness of CAPD. Innovations include ergonomic catheter designs and rapid exchange sets that simplify the use of catheters at home for patients and caregivers.

Based on end user, the peritoneal dialysis equipment market is categorized into in-center dialysis settings

home care settings. The in-center dialysis settings segment held a larger share of the market in 2024. In-center peritoneal dialysis (PD) facilities remain crucial in the global renal care landscape, particularly in regions where home dialysis programs are underdeveloped. Such places offer patients the supervision and assistance of professionals, thus ensuring the proper technique and minimizing the risk of complications.

Companies operating in the peritoneal dialysis equipment market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key Peritoneal Dialysis Equipment market players are listed below.

In March 2025, Fresenius Medical Care (FME) expanded production of bibag dry bicarbonate concentrate bags for hemodialysis in its Jaguari?na factory, in the state of Sao Paulo, Brazil. Fresenius Medical Care started the new production of bibag in March of 2025. The FME plant, located in the city of Jaguari?na, now produces bibag in a high-level automated production line for the domestic market in Brazil, as well as for export to various Latin American countries.

In April 2024, Fresenius Medical Care (FME), has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers. The company has in parallel launched the newest version of its home dialysis machine, the NxStage VersiHD with GuideMe Software, featuring enhancements designed to simplify treatment, increase ease of learning, and improve user experience.